BRCA2 and neoplasm: Therefore, tumor-based gene panel testing (FoundationOne®, Foundation Medicine Inc., Cambridge, MA, USA) was performed to evaluate the suitability of PARP inhibitors, which identified a pathogenic BRCA2 mutation (R2318*) with a variant allele frequency (VAF) of 71.52%.